<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858481</url>
  </required_header>
  <id_info>
    <org_study_id>SPN-201-05</org_study_id>
    <secondary_id>HTR-124235</secondary_id>
    <nct_id>NCT00858481</nct_id>
  </id_info>
  <brief_title>A Pilot Dose Ranging Study of Spinosad Creme Rinse</brief_title>
  <official_title>Efficacy and Safety of Different Strengths of Spinosad Topical Creme (0%, 0.5%, 1.0% or 2%) in Subjects With Pediculosis Capitis - a Dose Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ParaPRO LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ParaPRO LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot dose ranging study to evaluate the safety and efficacy of different strengths of&#xD;
      Spinosad Creme versus a vehicle control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2a, randomized, single investigational site, investigator/evaluator-blind, four-arm,&#xD;
      parallel-group, vehicle-controlled, pilot study to evaluate the safety and efficacy of&#xD;
      different strengths of Spinosad Creme rinse verses vehicle control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of various doses of Spinosad, based on the presence or absence of live lice at 7 and 14 days post-treatment. The efficacy evaluation was performed by a trained evaluator.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of various doses of Spinosad, based on the occurrence of adverse events, especially scalp irritation.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pediculosis Capitis</condition>
  <condition>Head Lice</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% Spinosad creme rinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0% Spinosad Creme Rinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.0% Spinosad Creme Rinse</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinosad Creme Rinse - Vehicle Control</intervention_name>
    <description>One or two, 10-minute topical applications (7 days apart)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinosad Creme Rinse</intervention_name>
    <description>0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinosad Creme Rinse</intervention_name>
    <description>1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinosad Creme Rinse</intervention_name>
    <description>2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active head lice infestation&#xD;
&#xD;
          -  Male or female, 2 years of age or older&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  Appropriately signed Informed Consent&#xD;
&#xD;
          -  Subject agreement to not use any other form of lice treatment during the course of the&#xD;
             study&#xD;
&#xD;
          -  Subject agreement to not cut or chemically treat their hair between visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of irritation or sensitivity to pediculicides or hair care products&#xD;
&#xD;
          -  Individuals with any visible skin/scalp condition that would interfere with the&#xD;
             evaluation&#xD;
&#xD;
          -  Individuals previously treated with a pediculicide within 4 weeks prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Individuals using hair dyes, bleaches, permanent waves or relaxing solutions 2 weeks&#xD;
             prior to study enrollment&#xD;
&#xD;
          -  Individuals who have participated in any clinical trial within 30 days of enrollment&#xD;
&#xD;
          -  Individuals with family members who were infested with lice but were unwilling or&#xD;
             unable to enroll in the study or use a standard course of lice treatment&#xD;
&#xD;
          -  Females who were pregnant or nursing&#xD;
&#xD;
          -  Sexually active females not using effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dyal Garg, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hill Top Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hill Top Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dyal Garg, Ph.D., Principal Investigator</name_title>
    <organization>Hill Top Research</organization>
  </responsible_party>
  <keyword>Pediculosis capitis</keyword>
  <keyword>Head Lice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

